Can the morbidly obese asthmatic child be well controlled? The Breathmobile program Stanley P. Galant, MD FAAAAI; CHOC, Orange, CA. RATIONALE: The obese asthmatic is thought to disproportionally experience greater severity, morbidity, increased exacerbations, and reduced inhaled corticosteroid responsiveness. We have previously reported that care provided by a community-based healthcare delivery system, the Breathmobile, results in improved asthma control, and reduced morbidity. We hypothesized that this system of care could provide similar outcomes for the morbidly obese compared to the normal weight asthmatic child.
RATIONALE: An asthma medication ratio (AMR) > _0.5 is associated with decreased healthcare utilization improving patient-centered outcomes in persistent asthma. There is limited literature on outcomes after restricting short acting beta-agonist (SABA) refills. We hypothesized that a multidisciplinary SABA-Reduction Program (SABA-RP), which included limitations on refills, would significantly increase the percentage of patients fulfilling an AMR of > _0.5, the number of asthma controller medications (CM) divided by the total of asthma medications (CM plus SABA). METHODS: A retrospective observational study of 1,084 patients, ages 18-65, with asthma fulfilling Health Effectiveness Data and Information Set (HEDIS) criteria was performed using data from Kaiser Permanente, Northern California (KPNC) in San Francisco. The SABA-RP consisted of both group and individual intensive asthma education of primary providers, patient outreach, and pharmacists changing SABA refills to zero. The program began April 1, 2015, and the study looked at one year prior and one year post-SABA-RP. Analysis included descriptive statistics, paired and unpaired t-tests, and multivariable logistic regression. RESULTS: 71% of patients met an AMR goal > _0.5 prior to implementation of the SABA-RP, while 84% met the goal after implementation (p<0.01). There was no statistically significant association between ED/ hospitalizations and meeting the AMR goal. Multivariable logistic regression showed younger, male, or Black/Hispanic subjects had significantly lower odds of meeting the AMR goal post-SABA-RP. CONCLUSIONS: Multidisciplinary change through implementation of a SABA-RP was associated with a higher number of patients fulfilling an AMR goal > _0.5 in this large retrospective cohort study at KPNC. We conducted a retrospective analysis of 132 subjects with VCD seen at an outpatient university allergy clinic. VCD diagnosis was confirmed with flexible laryngoscopy. We compared the demographics, comorbidities, clinical symptoms and medication use of VCD subjects with predominantly upper airway symptoms mimicking anaphylaxis versus those with predominantly lower airway symptoms mimicking asthma or other respiratory disorders. RESULTS: Twelve subjects (9.1%) had symptoms that mimicked those of upper airway obstruction. There was no difference in age (p50.3) or gender (p50.7) between the two groups. VCD subjects with upper airway symptoms were more likely to have a past medical history of food allergy (p50.003), chronic urticaria/angioedema (p50.009), and psychiatric illnesses (p50.005), but were less likely to have a history of pulmonary disease (p50.002). The patients with upper airway symptoms were also more likely to experience dysphonia (p50.002), stress and anxiety (p50.002), and be prescribed epinephrine (p<0.0001) or psychiatric medications (p50.04). CONCLUSIONS: VCD mimicking anaphylaxis has a lower prevalence than VCD mimicking asthma in a university allergy clinic. VCD patients misdiagnosed with anaphylaxis have distinguishing symptoms, comorbidities, and medication use compared to VCD patients misdiagnosed with asthma or other pulmonary disorders. Recognizing this unique population can lead to timely diagnosis and prevent mistreatment with unnecessary medications and procedures.
